Literature DB >> 14532292

Mullerian inhibiting substance promotes interferon gamma-induced gene expression and apoptosis in breast cancer cells.

Yasunori Hoshiya1, Vandana Gupta, Hirofumi Kawakubo, Elena Brachtel, Jennifer L Carey, Laura Sasur, Andrew Scott, Patricia K Donahoe, Shyamala Maheswaran.   

Abstract

This report demonstrates that in addition to interferons and cytokines, members of the TGF beta superfamily such as Mullerian inhibiting substance (MIS) and activin A also regulate IRF-1 expression. MIS induced IRF-1 expression in the mammary glands of mice in vivo and in breast cancer cells in vitro and stimulation of IRF-1 by MIS was dependent on activation of the NF kappa B pathway. In the rat mammary gland, IRF-1 expression gradually decreased during pregnancy and lactation but increased at involution. In breast cancer, the IRF-1 protein was absent in 13% of tumors tested compared with matched normal glands. Consistent with its growth suppressive activity, expression of IRF-1 in breast cancer cells induced apoptosis. Treatment of breast cancer cells with MIS and interferon gamma (IFN-gamma) co-stimulated IRF-1 and CEACAM1 expression and synergistic induction of CEACAM1 by a combination of MIS and IFN-gamma was impaired by antisense IRF-1 expression. Furthermore, a combination of IFN-gamma and MIS inhibited the growth of breast cancer cells to a greater extent than either one alone. Both reagents alone significantly decreased the fraction of cells in the S-phase of the cell cycle, an effect not enhanced when they were used in combination. However, MIS promoted IFN-gamma-induced apoptosis demonstrating a functional interaction between these two classes of signaling molecules in regulation of breast cancer cell growth.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14532292     DOI: 10.1074/jbc.M307626200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  Circulating anti-Müllerian hormone and breast cancer risk: A study in ten prospective cohorts.

Authors:  Wenzhen Ge; Tess V Clendenen; Yelena Afanasyeva; Karen L Koenig; Claudia Agnoli; Louise A Brinton; Joanne F Dorgan; A Heather Eliassen; Roni T Falk; Göran Hallmans; Susan E Hankinson; Judith Hoffman-Bolton; Timothy J Key; Vittorio Krogh; Hazel B Nichols; Dale P Sandler; Minouk J Schoemaker; Patrick M Sluss; Malin Sund; Anthony J Swerdlow; Kala Visvanathan; Mengling Liu; Anne Zeleniuch-Jacquotte
Journal:  Int J Cancer       Date:  2018-02-08       Impact factor: 7.396

2.  Mullerian inhibiting substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma model.

Authors:  V Gupta; J L Carey; H Kawakubo; A Muzikansky; J E Green; P K Donahoe; D T MacLaughlin; S Maheswaran
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-22       Impact factor: 11.205

3.  Plasma Anti-Müllerian Hormone Concentrations and Risk of Breast Cancer among Premenopausal Women in the Nurses' Health Studies.

Authors:  A Heather Eliassen; Anne Zeleniuch-Jacquotte; Bernard Rosner; Susan E Hankinson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-03-09       Impact factor: 4.254

Review 4.  Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers.

Authors:  David T MacLaughlin; Patricia K Donahoe
Journal:  Future Oncol       Date:  2010-03       Impact factor: 3.404

5.  Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.

Authors:  Rafael Pieretti-Vanmarcke; Patricia K Donahoe; Lisa A Pearsall; Daniela M Dinulescu; Denise C Connolly; Elkan F Halpern; Michael V Seiden; David T MacLaughlin
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-06       Impact factor: 11.205

6.  IRF-1 inhibits NF-κB activity, suppresses TRAF2 and cIAP1 and induces breast cancer cell specific growth inhibition.

Authors:  Michaele J Armstrong; Michael T Stang; Ye Liu; Jin Yan; Eva Pizzoferrato; John H Yim
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

7.  Development of an efficiently cleaved, bioactive, highly pure FLAG-tagged recombinant human Mullerian Inhibiting Substance.

Authors:  Thanos D Papakostas; Rafael Pieretti-Vanmarcke; Fotini Nicolaou; Aristomenis Thanos; George Trichonas; Xanthi Koufomichali; Kosisochukwu Anago; Patricia K Donahoe; Jose Teixeira; David T MacLaughlin; Demetrios Vavvas
Journal:  Protein Expr Purif       Date:  2009-09-13       Impact factor: 1.650

8.  The Role of Interferon Regulatory Factor-1 (IRF1) in Overcoming Antiestrogen Resistance in the Treatment of Breast Cancer.

Authors:  J L Schwartz; A N Shajahan; R Clarke
Journal:  Int J Breast Cancer       Date:  2011-07-03

Review 9.  Müllerian inhibiting substance/anti-Müllerian hormone: A novel treatment for gynecologic tumors.

Authors:  Jang Heub Kim; David T MacLaughlin; Patricia K Donahoe
Journal:  Obstet Gynecol Sci       Date:  2014-09-17

10.  A novel approach in the treatment of neuroendocrine gastrointestinal tumors: additive antiproliferative effects of interferon-gamma and meta-iodobenzylguanidine.

Authors:  Michael Höpfner; Andreas P Sutter; Alexander Huether; Gudrun Ahnert-Hilger; Hans Scherübl
Journal:  BMC Cancer       Date:  2004-05-21       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.